16 completed. 16 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 16 |
| Phase 2 | 1 | Completed 1 |
Follow Chorea: new trials by email Literature Review of Chorea trials Research Report on Chorea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Placebo, Valbenazine - Dyskinesia, Cerebral Palsy | Phase 3 | Completed | Neurocrine Biosciences | 86 | 2022-04-15 | 2026-04-29 |
| TEsting METformin Against Cognitive Decline in HD Metformin, Placebo - Huntington Disease | Phase 3 | Completed | Instituto de Investigacion Sanitaria La Fe | 60 | 2022-04-11 | 2025-09-25 |
| PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD Pridopidine, Placebo - Huntington Disease | Phase 3 | Completed | Prilenia | 499 | 2020-10-16 | 2025-03-12 |
| Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease Valbenazine, Placebo - Chorea, Huntington | Phase 3 | Completed | Neurocrine Biosciences | 128 | 2019-11-13 | 2023-10-11 |
| Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), Placebo - Huntington Disease, Irritability | Phase 3 | Completed | The University of Texas Health Science Center, Houston | 20 | 2019-08-05 | 2024-01-05 |
| An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies RO7234292 (RG6042) - Huntington Disease | Phase 3 | Completed | Hoffmann-La Roche | 236 | 2019-04-23 | 2023-08-31 |
| A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease RO7234292, Placebo - Huntingtons Disease | Phase 3 | Completed | Hoffmann-La Roche | 899 | 2019-01-23 | 2024-03-01 |
| Alternatives for Reducing Chorea in Huntington Disease SD-809 - Chorea Associated With Huntington Disease | Phase 3 | Completed | Auspex Pharmaceuticals, Inc. | 119 | 2013-11-12 | 2021-11-09 |
| First Time Use of SD-809 in Huntington Disease SD-809, Placebo - Chorea | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 90 | 2013-08-05 | 2017-09-20 |
| A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease Dimebon, Placebo - Huntington Disease | Phase 3 | Completed | Medivation, Inc. | 403 | 2009-07-01 | 2016-10-12 |
| Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride Olanzapine, Xenazine, Tiapridal - Huntington Disease | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 180 | 2009-04-01 | 2018-01-19 |
| A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease ACR16, Placebo - Huntington's Disease | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 437 | 2008-04-24 | 2023-08-29 |
| Pilot Study of Minocycline in Huntington's Disease minocycline, Matching placebo - Huntington Disease | Phase 2 / Phase 3 | Completed | Merit Cudkowicz | 114 | 2006-04-01 | 2013-04-19 |
| TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease Ethyl-EPA (Miraxion™) - Huntington Disease | Phase 3 | Completed | Amarin Neuroscience Ltd | 300 | 2005-09-01 | 2007-12-27 |
| Riluzole in Huntington's Disease Riluzole - Huntington Disease | Phase 3 | Completed | Sanofi | 537 | 1999-11-01 | 2012-02-17 |
| Efficacy and Safety of Tetrabenazine in Chorea tetrabenazine or placebo - Huntington's Disease | Phase 3 | Completed | Prestwick Pharmaceuticals | 2005-09-22 |
Huntington Disease (14) · Athetosis (1) · Cerebral Palsy (1) · Dyskinesias (1) · Dystonia (1) · Lymphoma, Follicular (1) · Movement Disorders (1)
Central Nervous System Diseases (16) · Nervous System Diseases (16) · Brain Diseases (15) · Dyskinesias (15) · Movement Disorders (15) · Basal Ganglia Diseases (14) · Cognition Disorders (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Dementia (14) · Genetic Diseases, Inborn (14) · Heredodegenerative Disorders, Nervous System (14) · Mental Disorders (14) · Neurocognitive Disorders (14) · Neurodegenerative Diseases (14)
Tetrabenazine (2) · deutetrabenazine (2) · pridopidine (2) · tominersen (2) · valbenazine (2) · Biguanides (1) · Dextromethorphan (1) · Docosahexaenoic Acids (1) · Hypoglycemic Agents (1) · Metformin (1) · Minocycline (1) · Olanzapine (1) · Quinidine (1) · Riluzole (1) · Tiapride Hydrochloride (1)
Hoffmann-La Roche (2) · Neurocrine Biosciences (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Amarin Neuroscience Ltd (1) · Assistance Publique - Hôpitaux de Paris (1) · Auspex Pharmaceuticals, Inc. (1) · Instituto de Investigacion Sanitaria La Fe (1) · Medivation, Inc. (1) · Merit Cudkowicz (1) · Prestwick Pharmaceuticals (1) · Prilenia (1) · Sanofi (1) · The University of Texas Health Science Center, Houston (1)
United States (11) · Canada (9) · Spain (6) · Germany (5) · Italy (5) · United Kingdom (5) · Australia (4) · Austria (4) · France (4) · Netherlands (3) · Poland (3) · Argentina (2) · Belgium (2) · Denmark (2) · Portugal (2)
Blair Leavitt, MD (1) · Christopher Ross, MD, PhD (1) · Erin L Furr Stimming, MD (1) · Fred Marshall, M.D. (1) · Ira Shoulson, MD (1) · Merit E. Cudkowicz, MD (1) · Yael Cohen (1)
PMID 28265459, PMID 38557959, PMID 39825184, PMID 19064745, PMID 20021666, PMID 22071279, PMID 23108692, PMID 26714284, PMID 27380342, PMID 29480210, PMID 30776019, PMID 31381524, PMID 32250312, PMID 36242718, PMID 36811812, PMID 37210099, PMID 40913168, PMID 41499296, PMID 42032152
2018 (1)